The preferred crystalline, solution, and in vacuo arrangements of 1-[[1- [2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone (BMY-21502) were investigated by means of single-crystal X-ray diffraction, 1H and 13C NMR spectroscopy, and semiempirical molecular orbital and molecular mechanics calculations. The X-ray powder diffraction pattern is also reported
X-RAY, NMR, and Theoretical Studies of the Nootropic Agent BMY-21502, a Pyrrolidinone Derivative
Tisato F
1994
Abstract
The preferred crystalline, solution, and in vacuo arrangements of 1-[[1- [2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone (BMY-21502) were investigated by means of single-crystal X-ray diffraction, 1H and 13C NMR spectroscopy, and semiempirical molecular orbital and molecular mechanics calculations. The X-ray powder diffraction pattern is also reportedFile in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
prod_224969-doc_146451.pdf
solo utenti autorizzati
Descrizione: X-RAY, NMR, and Theoretical Studies of the Nootropic Agent BMY-21502, a Pyrrolidinone Derivative
Tipologia:
Versione Editoriale (PDF)
Dimensione
3.37 MB
Formato
Adobe PDF
|
3.37 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
